These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27856730)

  • 21. Impact of carbapenem restriction on the antimicrobial susceptibility pattern of Pseudomonas aeruginosa isolates in the ICU.
    Abdallah M; Badawi M; Amirah MF; Rasheed A; Mady AF; Alodat M; Alharthy A
    J Antimicrob Chemother; 2017 Nov; 72(11):3187-3190. PubMed ID: 28961733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.
    Sader HS; Castanheira M; Duncan LR; Flamm RK
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):69-74. PubMed ID: 29789189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.
    Tartof SY; Kuntz JL; Chen LH; Wei R; Puzniak L; Tian Y; Im TM; Takhar HS; Merchant S; Lodise T
    JAMA Netw Open; 2018 Oct; 1(6):e183927. PubMed ID: 30646267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of a multimodal strategy combining a new standard of care and restriction of carbapenems, fluoroquinolones and cephalosporins on antibiotic consumption and resistance of Pseudomonas aeruginosa in a French intensive care unit.
    Abbara S; Pitsch A; Jochmans S; Hodjat K; Cherrier P; Monchi M; Vinsonneau C; Diamantis S
    Int J Antimicrob Agents; 2019 Apr; 53(4):416-422. PubMed ID: 30537533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
    Lodise TP; Miller CD; Graves J; Furuno JP; McGregor JC; Lomaestro B; Graffunder E; McNutt LA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):417-22. PubMed ID: 17158943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015.
    Walters MS; Grass JE; Bulens SN; Hancock EB; Phipps EC; Muleta D; Mounsey J; Kainer MA; Concannon C; Dumyati G; Bower C; Jacob J; Cassidy PM; Beldavs Z; Culbreath K; Phillips WE; Hardy DJ; Vargas RL; Oethinger M; Ansari U; Stanton R; Albrecht V; Halpin AL; Karlsson M; Rasheed JK; Kallen A
    Emerg Infect Dis; 2019 Jul; 25(7):1281-1288. PubMed ID: 31211681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2009 Sep; 57():636, 638-40, 645. PubMed ID: 20214000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of multi-drug resistant Pseudomonas aeruginosa infections on acute pancreatitis patients.
    Wu D; Lu W; Huang Y; Qin G; Liu H; Xiao J; Peng J
    BMC Infect Dis; 2023 May; 23(1):340. PubMed ID: 37217844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of Multidrug-Resistant
    Kresken M; Wohlfarth E; Wichelhaus TA; Gatermann SG; Pfennigwerth N; Eisfeld J; Seifert H;
    Microb Drug Resist; 2023 Apr; 29(4):138-144. PubMed ID: 36622756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
    Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
    Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal Carbapenem-Resistant Pseudomonas aeruginosa.
    Hu Y; Qing Y; Chen J; Liu C; Lu J; Wang Q; Zhen S; Zhou H; Huang L; Zhang R
    Microbiol Spectr; 2021 Dec; 9(3):e0134421. PubMed ID: 34817230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.
    Marner M; Kolberg L; Horst J; Böhringer N; Hübner J; Kresna IDM; Liu Y; Mettal U; Wang L; Meyer-Bühn M; Mihajlovic S; Kappler M; Schäberle TF; von Both U
    Microbiol Spectr; 2023 Feb; 11(1):e0443722. PubMed ID: 36692293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
    Rutter WC; Burgess DR; Burgess DS
    Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Clinical Specimens in Tertiary Care Hospital.
    Sharma S; Devkota MD; Pokhrel BM; Banjara MR
    J Nepal Health Res Counc; 2023 Mar; 20(3):586-592. PubMed ID: 36974842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of carbapenemase genes among multidrug-resistant
    Saengsuwan P; Kositpantawong N; Kawila S; Patugkaro W; Romyasamit C
    Saudi Med J; 2022 Sep; 43(9):991-999. PubMed ID: 36104060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.